[Ditazol in the therapy of ischemic cerebrovascular diseases. Clinical results and laboratory experiments (22-to-34-month clinical follow-up)].
A sample of 29 patients suffering from ischaemic cerebrovascular disorders was examined. Of these, 15 were treated with Ditazol (1200 mg/day in three administrations) and 14 with ASA (1 g a day in 2 administration). These patients were evaluated using serial Born and Cross tests to check ADP, Adrenaline and Collagen-induced platelet aggregation. The clinical follow-up lasted 22-34 months. As part of the laboratory evaluation, this sample was also compared with a group of 34 healthy volunteers. Ditazol was found to be an inhibitor of ADP, Adrenaline and Collagen-induced platelet aggregation: this effect constitutes clinical protection against recurrence of the complaint. Recurrence was 13.3% with Ditazol treated patients and 35.7% with ASA.
Caneschi
S
S
Bonaventi
C
C
Finzi
F
F
Tito
P
P
D000244:Adenosine Diphosphate / Q000494:pharmacology; D000328:Adult; D000368:Aged; D001241:Aspirin / Q000627:therapeutic use; D002545:Brain Ischemia / Q000188:drug therapy*; D003094:Collagen / Q000494:pharmacology; D004837:Epinephrine / Q000494:pharmacology; D005260:Female; D006801:Humans; D002546:Ischemic Attack, Transient / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010080:Oxazoles / Q000627:therapeutic use*; D010974:Platelet Aggregation / Q000187:drug effects
D010080:Oxazoles; D000244:Adenosine Diphosphate; D003094:Collagen; D001241:Aspirin; D004837:Epinephrine
Il ditazolo nella terapia delle vasculopatie cerebrali ischemiche. Risultati clinici ed esperienze di laboratorio (follow-up clinico 22-34 mesi).